drugset / Trial / NCT06146985
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-cohort, open-label, single-centre, Phase 2 study aiming to investigate the efficacy and safety of a regimen using the multi-targeted kinase inhibitor Famitinib in combination with the PD-L1 antibody Adebrelimab for the patients with unresectable locally advanced or metastatic refractory to standard treatment differentiated thyroid cancer (DTC), medullary thyroid carcinoma (MTC) as well as Anaplastic thyroid carcinoma (ATC).
Timeline
- Start
- 2023-12-01
- Primary completion
- 2024-11-15
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Famitinib | Small molecule | 20 mg | Oral |